Correction to: Ventilator-associated pneumonia in critically ill patients with COVID-19

Maes, Mailis; Higginson, Ellen E.; Pereira-Dias, Joana; Curran, Martin D.; Parmar, Surendra; Khokhar, Fahad; Cuchet-Lourenço, Delphine; Lux, Janine; Sharma-Hajela, Sapna; Ravenhill, Benjamin; Hamed, Islam; Heales, Laura; Mahroof, Razeen; Soderholm, Amelia T.; Forrest, Sally; Sridhar, Sushmita; Brown, Nicholas M.; Baker, Stephen; Navapurkar, Vilas; Dougan, Gordon; Scott, Josefn Bartholdson; Morris, Andrew Conway

doi:10.1186/s13054-021-03560-2

Cited by 33 publications

(29 citation statements)

References 2 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Little is known about the epidemiology of VAP in COVID- 19 patients. An European multicenter study including 568 cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection reported that the VAP incidence and ventilator-acquired tracheobronchitis were higher compared with the general population and influenza patients undergoing mechanical ventilation and reported that the majority of bacteria responsible for VAP were Gram-negative (Pseudomonas aeruginosa, Enterobacter species, and Klebsiella species) (16); similar results were found in the study reported by Maes et al (17) or Blonz et al (18). These concordant studies indicate that the incidence of VAP among COVID-19 patients is higher than that would be expected from other viral pneumonia.…”

supporting

confidence: 73%

Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*

Vacheron

Lepape

Savey

et al. 2021

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

supporting

confidence: 73%

Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*

Vacheron

Lepape

Savey

et al. 2021

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…higher VAP incidence rates: United Kingdom (10): 28 per 1,000 ventilation days; Italy (11): 26 per 1,000 ventilation days; in fact, the hazard ratio shown in Maes et al (10) (2.01; 95% CI, 1.14-3.54; p = 0.001) was similar to that from Vacheron et al (9).…”

supporting

confidence: 60%

Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?*

Kalil

Cawcutt

2021

Critical Care Medicine

View full text Add to dashboard Cite

Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Study Group; Corticosteroid Randomisation After Significant Head Injury (CRASH) Trial Collaborators; Trauma Audit and Research Network (TARN): Prediction of outcome after moderate and severe traumatic brain injury: External validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models.

show abstract

“…We found that invasive ventilation was a relevant risk factor for CAPA which is known as important risk factors for ventilator-associated pneumonia (VAP) in general [44]. Nevertheless, one study compared ventilated COVID-19 patients with non-COVID-19 ventilated patients and found an increased incidence overall of VAP (including CAPA) associated with COVID-19 [45]. Another author then suggested early prophylaxis with antifungal agents for critically ill COVID-19 patients [22].…”

Section: Other Risk Factorsmentioning

confidence: 99%

Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients

et al. 2022

View full text Add to dashboard Cite

Purpose Corticosteroids, in particular dexamethasone, are one of the primary treatment options for critically ill COVID-19 patients. However, there are a growing number of cases that involve COVID-19-associated pulmonary aspergillosis (CAPA), and it is unclear whether dexamethasone represents a risk factor for CAPA. Our aim was to investigate a possible association of the recommended dexamethasone therapy with a risk of CAPA. Methods We performed a study based on a cohort of COVID-19 patients treated in 2020 in our 13 intensive care units at Charité Universitätsmedizin Berlin. We used ECMM/ISHM criteria for the CAPA diagnosis and performed univariate and multivariable analyses of clinical parameters to identify risk factors that could result in a diagnosis of CAPA. Results Altogether, among the n = 522 intensive care patients analyzed, n = 47 (9%) patients developed CAPA. CAPA patients had a higher simplified acute physiology score (SAPS) (64 vs. 53, p < 0.001) and higher levels of IL-6 (1,005 vs. 461, p < 0.008). They more often had severe acute respiratory distress syndrome (ARDS) (60% vs. 41%, p = 0.024), renal replacement therapy (60% vs. 41%, p = 0.024), and they were more likely to die (64% vs. 48%, p = 0.049). The multivariable analysis showed dexamethasone (OR 3.110, CI95 1.112–8.697) and SAPS (OR 1.063, CI95 1.028–1.098) to be independent risk factors for CAPA. Conclusion In our study, dexamethasone therapy as recommended for COVID-19 was associated with a significant three times increase in the risk of CAPA. Trial registration Registration number DRKS00024578, Date of registration March 3rd, 2021.

show abstract

Correction to: Ventilator-associated pneumonia in critically ill patients with COVID-19

Abstract: An amendment to this paper has been published and can be accessed via the original article.

Cited by 33 publications

References 2 publications

Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*

Increased Incidence of Ventilator-Acquired Pneumonia in Coronavirus Disease 2019 Patients: A Multicentric Cohort Study*

Is Ventilator-Associated Pneumonia More Frequent in Patients With Coronavirus Disease 2019?*

Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients

Contact Info

Product

Resources

About